FICOCYTE
FICOCYTE 48 MU
Therapeutic indications
Fycocyte is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
The safety and efficacy of Fycocyte are similar in adults and children receiving cytotoxic chemotherapy.
Fycocyte is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of 
0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Fycocyte is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Fycocyte is indicated for the treatment of persistent neutropenia (Absolute neutrophil count (ANC) less than or equal to 1.0 x109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate
Download details FICOCYTE 48
Download details FICOCYTE 30
